지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.8
- 수록면
- 325 - 336 (12page)
이용수
초록· 키워드
오류제보하기
Backgrounds/Aims: The efficacy of neoadjuvant transarterial chemoembolization (N−TACE) in resectable hepatocellular carcinoma (HCC) remains open to debate. While N−TACE may reduce tumor size, its impact on long-term outcomes is inconclusive.
Methods: This meta-analysis reviewed studies on N−TACE before surgical resection vs. liver resection (LR) single large hepatocellular carcinoma (SLHCC) up to March 2023 from four online databases.
Results: Five studies with 1,556 patients were analyzed. No significant differences between N−TACE and LR groups were observed in 1-, 3-, or 5-year overall survival (OS) and disease-free survival (DFS). No significant differences were noted in intraoperative blood loss between groups. Subgroup analysis showed favorable 1-, 3-, and 5-year OS with combination chemotherapy N−TACE (combination group), and better 1-year OS in the LR group with single-agent chemotherapy N−TACE (single-agent group). Five-year DFS favored LR in the single-agent group, and N−TACE in the combination group.
Conclusions: Managing SLHCC requires intricate considerations, and the treatment strategies for this challenging subgroup of HCC need to be improved. The influence of N−TACE on long-term survival depends on the specific chemotherapy regimen employed, and its impact on intraoperative blood loss in SLHCC appears limited.
Methods: This meta-analysis reviewed studies on N−TACE before surgical resection vs. liver resection (LR) single large hepatocellular carcinoma (SLHCC) up to March 2023 from four online databases.
Results: Five studies with 1,556 patients were analyzed. No significant differences between N−TACE and LR groups were observed in 1-, 3-, or 5-year overall survival (OS) and disease-free survival (DFS). No significant differences were noted in intraoperative blood loss between groups. Subgroup analysis showed favorable 1-, 3-, and 5-year OS with combination chemotherapy N−TACE (combination group), and better 1-year OS in the LR group with single-agent chemotherapy N−TACE (single-agent group). Five-year DFS favored LR in the single-agent group, and N−TACE in the combination group.
Conclusions: Managing SLHCC requires intricate considerations, and the treatment strategies for this challenging subgroup of HCC need to be improved. The influence of N−TACE on long-term survival depends on the specific chemotherapy regimen employed, and its impact on intraoperative blood loss in SLHCC appears limited.
목차
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
Clinical and Molecular Hepatology
2021 .01
-
Outcomes of liver resection and transarterial chemoembolization in patients with multinodular BCLC-A hepatocellular carcinoma
Journal of Liver Cancer
2024 .09
-
Transcatheter Arterial Chemoembolization Combined with Interferon-α is Safe and Effective for Patients with Hepatocellular Carcinoma after Curative Resection
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Rare Case of Pyogenic Brain Abscess after Transarterial Chemoembolization in a Patient with Hepatocellular Carcinoma: Case Report and Literature Review
Journal of Liver Cancer
2021 .01
-
Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery
Journal of Liver Cancer
2020 .01
-
Ruptured Massive Hepatocellular Carcinoma Cured by Transarterial Chemoembolization
Journal of Liver Cancer
2020 .01
-
The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
Clinical and Molecular Hepatology
2017 .01
-
Efficacy of Transarterial Chemoembolization Combined with Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
Clinical and Molecular Hepatology
2020 .01
-
Hepatic Resection after Initial Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Rupture of hepatocellular carcinoma after transcatheter arterial chemoembolization: A case report
International Journal of Gastrointestinal Intervention
2021 .01
-
Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria
Annals of Surgical Treatment and Research
2020 .10
-
Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion
Clinical and Molecular Hepatology
2018 .01
-
Clinical usefulness of transarterial chemoembolization response prior to liver transplantation as predictor of optimal timing for living donor liver transplantation
Annals of Surgical Treatment and Research
2018 .08
-
Patients with Spontaneously Ruptured Hepatocellular Carcinoma Benefit from Staged Surgical Resection after Successful Transarterial Embolization
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Current role of systemic therapy in transarterial chemotherapy-refractory hepatocellular carcinoma patients
International Journal of Gastrointestinal Intervention
2021 .10
-
Balloon-occluded transarterial chemoembolization for hepatocellular carcinoma: History, background, and the roles
International Journal of Gastrointestinal Intervention
2020 .01
-
Transarterial Chemoembolization Monotherapy in Combination with Radiofrequency Ablation or Percutaneous Ethanol Injection for Hepatocellular Carcinoma
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Transarterial chemoembolization versus resection for the intermediate stage hepatocellular carcinoma
Clinical and Molecular Hepatology
2016 .01
-
Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy
Journal of Liver Cancer
2024 .09
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-151-24-02-090278134